Advertisement

Related Videos

David A. Hyman, MD, JD, on Inclusive Shared Savings

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Peter Clark, MA, MD, FRCP: A Payer Perspective

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Advertisement

Advertisement




Apr
29
Today In Oncology
Tracking Biological Age Changes Gives Insights Into Cancer Prognosis
Neoadjuvant Durvalumab and Chemotherapy in Triple-Negative Breast Cancer: Long-Term Follow-Up of GeparNuevo Trial
Global Review Shows Impact of Exposure to Air Pollution on Cancer Risk and Mortality
Do Political Beliefs Shape Views on Clinical Trials in Cancer?
RAS Inhibitor Daraxonrasib in Metastatic Pancreatic Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo